Ibogaine therapy for substance abuse disorders

Deborah C Mash

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Citations (Scopus)

Abstract

Introduction Ibogaine is a naturally occurring psychoactive indole alkaloid derived from the roots of the rainforest shrub Tabernanthe iboga.Ibogaine is used by indigenous peoples of Western Africa in low doses to combat fatigue, hunger, and thirst, and in higher doses as a sacrament in religious rituals (Goutarel et al., 1991). The use of ibogaine for the treatment of drug dependence was based on anecdotal reports by groups of self-treating addicts that the drug blocked opiate withdrawal and reduced craving for opiates, cocaine, and other illicit drugs for extended time periods (Shepard, 1994; Alper et al., 1999). Preclinical studies supported these early claims and provided proof-of-concept in animal models (Dzoljic et al., 1988; Glick et al., 1992). Addiction is a behavioral pattern of drug abuse characterized by compulsive use, loss of behavioral control, and a high tendency to relapse. An integrated medical, psychosocial, and spiritual treatment is often needed to achieve recovery in addicted patients. Ibogaine is a unique pharmacotherapy for the treatment of substance abuse disorders because it fosters a life change or may work as a transition-based therapy similar to the goals set in the 12-step fellowship programs. While ibogaine's effects on behavior are complex, the beneficial actions of the drug on withdrawal symptoms and cravings are because of an interaction of the active metabolite noribogaine with neurotransmitters in the brain reward and addiction circuit.

Original languageEnglish (US)
Title of host publicationClinical Addiction Psychiatry
PublisherCambridge University Press
Pages50-60
Number of pages11
Volume9780521899581
ISBN (Print)9780511782107, 9780521899581
DOIs
StatePublished - Jan 1 2010

Fingerprint

Ibogaine
Substance-Related Disorders
Opiate Alkaloids
Tabernaemontana
Indole Alkaloids
Therapeutics
Thirst
Ceremonial Behavior
Substance Withdrawal Syndrome
Western Africa
Hunger
Street Drugs
Drug Users
Reward
Cocaine
Self Report
Fatigue
Neurotransmitter Agents
Animal Models
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mash, D. C. (2010). Ibogaine therapy for substance abuse disorders. In Clinical Addiction Psychiatry (Vol. 9780521899581, pp. 50-60). Cambridge University Press. https://doi.org/10.1017/CBO9780511782107.007

Ibogaine therapy for substance abuse disorders. / Mash, Deborah C.

Clinical Addiction Psychiatry. Vol. 9780521899581 Cambridge University Press, 2010. p. 50-60.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mash, DC 2010, Ibogaine therapy for substance abuse disorders. in Clinical Addiction Psychiatry. vol. 9780521899581, Cambridge University Press, pp. 50-60. https://doi.org/10.1017/CBO9780511782107.007
Mash DC. Ibogaine therapy for substance abuse disorders. In Clinical Addiction Psychiatry. Vol. 9780521899581. Cambridge University Press. 2010. p. 50-60 https://doi.org/10.1017/CBO9780511782107.007
Mash, Deborah C. / Ibogaine therapy for substance abuse disorders. Clinical Addiction Psychiatry. Vol. 9780521899581 Cambridge University Press, 2010. pp. 50-60
@inbook{f86cdae2d0cf44fa96c65c20dd751c62,
title = "Ibogaine therapy for substance abuse disorders",
abstract = "Introduction Ibogaine is a naturally occurring psychoactive indole alkaloid derived from the roots of the rainforest shrub Tabernanthe iboga.Ibogaine is used by indigenous peoples of Western Africa in low doses to combat fatigue, hunger, and thirst, and in higher doses as a sacrament in religious rituals (Goutarel et al., 1991). The use of ibogaine for the treatment of drug dependence was based on anecdotal reports by groups of self-treating addicts that the drug blocked opiate withdrawal and reduced craving for opiates, cocaine, and other illicit drugs for extended time periods (Shepard, 1994; Alper et al., 1999). Preclinical studies supported these early claims and provided proof-of-concept in animal models (Dzoljic et al., 1988; Glick et al., 1992). Addiction is a behavioral pattern of drug abuse characterized by compulsive use, loss of behavioral control, and a high tendency to relapse. An integrated medical, psychosocial, and spiritual treatment is often needed to achieve recovery in addicted patients. Ibogaine is a unique pharmacotherapy for the treatment of substance abuse disorders because it fosters a life change or may work as a transition-based therapy similar to the goals set in the 12-step fellowship programs. While ibogaine's effects on behavior are complex, the beneficial actions of the drug on withdrawal symptoms and cravings are because of an interaction of the active metabolite noribogaine with neurotransmitters in the brain reward and addiction circuit.",
author = "Mash, {Deborah C}",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511782107.007",
language = "English (US)",
isbn = "9780511782107",
volume = "9780521899581",
pages = "50--60",
booktitle = "Clinical Addiction Psychiatry",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Ibogaine therapy for substance abuse disorders

AU - Mash, Deborah C

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction Ibogaine is a naturally occurring psychoactive indole alkaloid derived from the roots of the rainforest shrub Tabernanthe iboga.Ibogaine is used by indigenous peoples of Western Africa in low doses to combat fatigue, hunger, and thirst, and in higher doses as a sacrament in religious rituals (Goutarel et al., 1991). The use of ibogaine for the treatment of drug dependence was based on anecdotal reports by groups of self-treating addicts that the drug blocked opiate withdrawal and reduced craving for opiates, cocaine, and other illicit drugs for extended time periods (Shepard, 1994; Alper et al., 1999). Preclinical studies supported these early claims and provided proof-of-concept in animal models (Dzoljic et al., 1988; Glick et al., 1992). Addiction is a behavioral pattern of drug abuse characterized by compulsive use, loss of behavioral control, and a high tendency to relapse. An integrated medical, psychosocial, and spiritual treatment is often needed to achieve recovery in addicted patients. Ibogaine is a unique pharmacotherapy for the treatment of substance abuse disorders because it fosters a life change or may work as a transition-based therapy similar to the goals set in the 12-step fellowship programs. While ibogaine's effects on behavior are complex, the beneficial actions of the drug on withdrawal symptoms and cravings are because of an interaction of the active metabolite noribogaine with neurotransmitters in the brain reward and addiction circuit.

AB - Introduction Ibogaine is a naturally occurring psychoactive indole alkaloid derived from the roots of the rainforest shrub Tabernanthe iboga.Ibogaine is used by indigenous peoples of Western Africa in low doses to combat fatigue, hunger, and thirst, and in higher doses as a sacrament in religious rituals (Goutarel et al., 1991). The use of ibogaine for the treatment of drug dependence was based on anecdotal reports by groups of self-treating addicts that the drug blocked opiate withdrawal and reduced craving for opiates, cocaine, and other illicit drugs for extended time periods (Shepard, 1994; Alper et al., 1999). Preclinical studies supported these early claims and provided proof-of-concept in animal models (Dzoljic et al., 1988; Glick et al., 1992). Addiction is a behavioral pattern of drug abuse characterized by compulsive use, loss of behavioral control, and a high tendency to relapse. An integrated medical, psychosocial, and spiritual treatment is often needed to achieve recovery in addicted patients. Ibogaine is a unique pharmacotherapy for the treatment of substance abuse disorders because it fosters a life change or may work as a transition-based therapy similar to the goals set in the 12-step fellowship programs. While ibogaine's effects on behavior are complex, the beneficial actions of the drug on withdrawal symptoms and cravings are because of an interaction of the active metabolite noribogaine with neurotransmitters in the brain reward and addiction circuit.

UR - http://www.scopus.com/inward/record.url?scp=84880152629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880152629&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511782107.007

DO - 10.1017/CBO9780511782107.007

M3 - Chapter

SN - 9780511782107

SN - 9780521899581

VL - 9780521899581

SP - 50

EP - 60

BT - Clinical Addiction Psychiatry

PB - Cambridge University Press

ER -